Identification of proangiogenic plasmatic biomarkers in patients with advanced grade 1/2 pancreatic (pan) and gastrointestinal (gi) neuroendocrine tumors (NETs) treated with Lenvatinib: A subanalysis from the TALENT phase II clinical trial

#3533

Introduction: TALENT phase II trial provided evidence of the efficacy of Lenvatinib in patients with panNETs and giNETs. However, no predictive biomarker has been associated to antiangiogenic treatment benefit to date.

Aim(s): Identify predictive biomarkers by evaluating a subset of proangiogenic molecules found in circulating plasma of patients included in the TALENT trial.

Materials and methods: Plasma samples were obtained from 84 patients prior to the start of Lenvatinib. Quantitative determinations of VEGF-A, FGF2, FGF4, Ang2, IL8, PlGF, VEGF-C, VEGF-D and VEGFR2 were analysed by multiplex ELISA with a custom made Quantibody Array. Protein levels of each biomarker were correlated with PFS, OS and ORR in the different subgroups included in the trial.

Conference:

Presenting Author: Garcia-Alvarez A

Authors: Garcia Alvarez A, Hernando J, Jimenez-Valero G, Martinez A, Fazio N,

Keywords: Lenvatinib, Angiogenesis, Ang2, VEGFR2,